- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Natco Pharma Ltd. (NATP)
The Natco Pharma share price today is 855.55, view NSE NATP stock exchange data. Track the latest Natco Pharma share price with real-time updates on NATP stock performance including market cap, day range, 52-week range and dividend yield. Access NATP charts, earnings dates and analyst estimates to support your investment decisions.
855.55
-7.85(-0.91%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
853.00
869.90
52 wk Range
789.00
1,226.80
NATP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
853.00869.90
52 wk Range
789.001,226.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.52%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.52%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
NATP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
1,004.44
Upside
+17.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
3 Hold
3 Sell
Ratings:
11 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1,004.44
(+17.40% Upside)
Natco Pharma Ltd. Earnings Call Summary for Q1/2027
- NATCO Pharma Q1 FY2027 revenue plunged 43% YoY to INR 794.4 crores due to lower lenalidomide sales; stock dropped 5.1% to $903.15.
- EBITDA margin improved to 30.9% with normalized PAT up 34% QoQ, driven by double-digit base business growth in oncology and semaglutide.
- Brazil revenue surged 180% YoY to INR 178 crores; domestic business grew to INR 136 crores with 25% volume growth expected for FY2027.
- Management maintained full-year guidance of INR 3,300-3,400 crores; carfilzomib launch on track for 2027, olaparib trial expected within two months.
- Company plans INR 2,000 crore fundraise for M&A and debt repayment; CEO emphasized long-term pipeline value materializing in 2-3 years.
Last Updated: 14-08-2026, 06:36 pm
Read Full TranscriptEarnings
Latest Release
14-08-2026
EPS / Forecast
11.50 / 6.40
Revenue / Forecast
7.35B / 7.55B
Compare NATP to Peers and Sector
Metrics to compare | NATP | Peers Peers - average of corresponding metrics from companies closely matching NATP: ALKEM, GLENMARK, SUNPHARMA, GLAND, AUROPHARMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNATPPeersSector |
|---|---|---|---|---|
P/E Ratio | 13.5x | 37.8x | −0.4x | |
PEG Ratio | −0.41 | 0.82 | 0.00 | |
Price/Book | 1.7x | 4.6x | 2.6x | |
Price / LTM Sales | 4.4x | 4.5x | 3.1x | |
Upside (Analyst Target) | 20.8% | 6.8% | 46.0% | |
Fair Value Upside | Unlock | −1.3% | 5.3% | Unlock |
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Natco Pharma (NATP) Share Price Today?
The Natco Pharma share price today is 855.55.
What is the current Natco Pharma (NATP) share price and day range?
As of 27-08-2026, the Natco Pharma share price is 855.55, with a previous close of 863.40. The share price has ranged from 853.00 to 869.90 today, while the 52-week range spans from 789.00 to 1,226.80.
What Is the Natco Pharma Market Cap?
As of today, Natco Pharma market cap is 153.32B.
Does Natco Pharma Pay Dividends? What's The Current Dividend Yield?
The Natco Pharma dividend yield is 0.52%.
What Is the Natco Pharma (NATP) Share Price Target?
The average 12-month share price target for Natco Pharma is 1,004.44, with a high estimate of 1180 and a low estimate of 712. 5 analysts recommend buying, while 3 suggest selling, with an overall rating of Neutral and +17.40% Upside potential.
What Is Natco Pharma's Earnings Per Share (TTM)?
The Natco Pharma EPS (TTM) is 63.89.
When Is the Next Natco Pharma Earnings Date?
Natco Pharma will release its next earnings report on 17-11-2026.
From a Technical Analysis Perspective, Is NATP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Natco Pharma Trade On?
Natco Pharma is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Natco Pharma?
The stock symbol for Natco Pharma is "NATP."
How Many Times Has Natco Pharma Stock Split?
Natco Pharma has split 1 times.
How Many Employees Does Natco Pharma Have?
Natco Pharma has 4199 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.